CLOs on the Move

Scribe Therapeutics

www.scribetx.com

 
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.scribetx.com
  • 1150 Marina Village Pkwy
    Alameda, CA USA 94501
  • Phone: 908.642.7374

Executives

Name Title Contact Details

Similar Companies

Soliance

Soliance is a Allendale, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Percivia

Percivia is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Seattle Genetics

Targeting Cancer. Transforming Therapies. Revolutionary science meets transformative cancer therapy Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency. In addition to one marketed product, we are advancing a strong product pipeline designed to address significant unmet medical needs.

Volcano Corporation

Volcano Corporation designs, develops, manufactures and commercializes a suite of intravascular ultrasound (IVUS) and functional measurement (FM) products that seeks to enhance the diagnosis and treatment of vascular and structural heart disease. The

Eiger BioPharmaceuticals

Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger`s pipeline includes preclinical NCEs from discovery as well repurposed clinical Rx agents shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses.